You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

QUADRA Trial Dosing

For Treatment of Advanced HRD+ Ovarian Cancer After Three or More Chemotherapies1

The approved starting dose of ZEJULA for treatment of advanced HRD+ ovarian cancer is 300 mg/day

ZEJULA Recommended Dose Modifications for Adverse Reactions1

+ Click to Zoomx Exit Zoom

ZEJULA (niraparib) starting dose based on baseline weight and/or platelet count

Adverse Reactions in QUADRA Were Consistent With Other Clinical Findings In NOVA1

Adverse reactions reported in ≥10% of patients receiving ZEJULA in QUADRA

+ Click to Zoomx Exit Zoom

Adverse reactions of ZEJULA (niraparib) in QUADRA

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Adverse reactions in QUADRA led to dose reduction or interruption, 73%1

Most frequently from:

  • Thrombocytopenia, 40%
  • Nausea, 13%
  • Fatigue, 9%
  • Anemia, 21%
  • Vomiting, 11%
  • Abdominal pain, 5%
  • Neutropenia, 11%

 

Discontinuation, 21%

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; CTCAE, Common Terminology Criteria for Adverse Events, version 4.02.

Efficacy data

EFFICACY DATA

View efficacy data for all indications

See the Data

Reference: 1. ZEJULA (niraparib). Prescribing Information. GlaxoSmithKline; 2020.